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CD95 (Fas/APO-1), when bound by its cognate ligand
CD95L, induces cells to die by apoptosis. We now
show that elimination of CD95 or CD95L results in a
form of cell death that is independent of caspase-8,
RIPK1/MLKL, and p53, is not inhibited by Bcl-xL
expression, and preferentially affects cancer cells.
All tumors that formed inmousemodels of low-grade
serous ovarian cancer or chemically induced liver
cancer with tissue-specific deletion of CD95 still ex-
pressed CD95, suggesting that cancer cannot form
in the absence of CD95. Death induced by CD95R/L
elimination (DICE) is characterized by an increase
in cell size, production of mitochondrial ROS, and
DNA damage. It resembles a necrotic form of mitotic
catastrophe. No single drug was found to completely
block this form of cell death, and it could also not be
blocked by the knockdown of a single gene, making
it a promising way to kill cancer cells.INTRODUCTION
CD95 (Fas/APO-1) is an apoptosis-inducing death receptor
(Peter and Krammer, 2003). However, CD95 also plays an
apoptosis-independent role in nonimmune cells, and it has
been implicated in cancer cell growth, migration, and tumor
progression (Martin-Villalba et al., 2013; Peter et al., 2007). We
previously showed that knockdown of either CD95 or CD95L
in multiple cancer cells led to growth reduction (Chen et al.,
2010). We also reported reduced tumor load in mouse models
of liver cancer and endometrioid ovarian cancer, both with tis-
sue-specific deletion of CD95 (Chen et al., 2010).
We now show that the CD95/CD95L system is critical for can-
cer cell survival with normal cells being less dependent. When
either gene was knocked down in a sustained fashion, cancer
cells showed substantial death induced by CD95R/L elimination
(DICE). An analysis of 12 independently performed genome-208 Cell Reports 7, 208–222, April 10, 2014 ª2014 The Authorsscale arrayed small hairpin RNA (shRNA) screens identified
CD95L as 1 of 651 essential survival genes. Tumor nodules
that grew out of two mouse models of ovarian and liver cancer
with tissue-specific CD95 deletion still expressed CD95, sug-
gesting a strong selection pressure for cancer cells to maintain
CD95 expression.
DICE is characterized by cell swelling and reactive oxygen
species (ROS) production followed by DNA damage, activation
of caspases, and loss of mitochondrial outer membrane per-
meabilization (MOMP). Cells die by a necrotic form of mitotic
catastrophe. We performed a small molecule screen and a
genome-wide shRNA screen but could not find a single drug
or a single gene that could either promote or block DICE. Our
data suggest that DICE represents multiple death pathways,
which indicates that cancer cells may not be able to acquire
resistance to DICE by mutations of single genes. This makes
DICE an attractive way to kill cancer cells.
RESULTS
Efficient and Sustained Reduction of CD95 or CD95L
Expression Drives Cancer Cells into Cell Death
Knockdown of either CD95 or CD95L by introducing either small
interfering RNAs (siRNAs) or lentiviral shRNAs in various cancer
cells caused reduction in growth within 3–5 days (Chen et al.,
2010). We now asked whether a profound and sustained knock-
down of CD95 or CD95L would cause the cells to die. Two inde-
pendent CD95L-specific shRNAs (L1 and L3) knocked down
CD95L as shown for the mouse colon carcinoma cell line CT26
stably expressing human CD95L (CT26L) (Aoki et al., 2001) and
the human hepatocellular carcinoma cell line HepG2 (Figure 1A).
Paralleling the knockdown efficiency of the different shRNAs,
we observed substantial numbers of dead cells in these cell lines
and multiple other cancer cell lines representing ovarian, breast,
renal, and colon cancer as well as glioblastoma (Figures 1B and
S1A). Cell death was quantified 9 days after infection with the
virus. Knockdown of CD95 using two independent shRNAs
also caused induction of cell death in a number of cancer cell
lines (Figures S1B and 2; Table S1). To exclude the possibility
of a puromycin effect, we infected T98G and HeyA8 cells with
Figure 1. Sustained Knockdown of CD95L
Induces Cell Death
(A) Western blot analysis tomonitor the expression
of human CD95L and b-actin in cells infected with
pLKO scr control, pLKO-L1, or pLKO-L3 after
4 days (CT26L) or 5 days (HepG2,MCF-7-vec, and
MCF-7 expressing CD95L). Level of knockdown
relative to b-actin is shown.
(B) Viability of eight cell lines 9 days after infection
with shRNA lentiviruses pLKO-L1, L3, or a control
virus carrying a scr shRNA (mean + SD of three
independent cultures). Two independent experi-
ments were quantified, yielding similar results.
(C) Left panel: MTS assays of MCF-7 cells 3 days
after mock treatment or transfection with 5 nM of
either a pool of four nontargeting siRNAs (Scr pool)
or a pool four siRNAs targeting CD95L (siCD95L
pool). OD, optical density. Right-bottom panel
shows nuclear PI staining of MCF-7 cells 4 days
after transfection with either Scr or siCD95L pool.
Data represent a representative experiment out of
three. Shown is the mean + SD from three inde-
pendent cultures. Right-top panel shows a west-
ern blot analysis of CD95L in MCF-7-CD95L cells
48 hr after transfection with 5 or 50 nM siCD95L.
(D) Quantification of cell death with nuclear PI
staining and DAPI staining in MCF-7 and HeyA8
cells transfected three times (3 days, 2 days,
2 days) with either a pool of four scr oligonucleo-
tides or a CD95L-specific siRNA SmartPool of four
siRNAs (mean +SDof three independent cultures).
(E) MCF-7 cells were transfected with either scr
pool or with the four individual SmartPool siRNAs
siL1–siL4. Transfection was carried out as in (D),
and cell death was quantified using nuclear PI
staining. Data represent a representative experi-
ment out of three. Shown is the mean + SD from
three independent cultures.
(F) Left panel: quantification of cell death in MCF-7 cells transfected with either unmodified siL3 or the same oligonucleotide with six single nucleotide
replacements (siL3mut). Shown is the mean + SD from three independent cultures. Data were reproduced with trypan blue exclusion assay. Right panel shows
sequences of siL3 and siL3mut and western blot analysis of MCF-7-CD95L cells 2 days after transfection with either a scr pool, one of the two oligonucleotides,
or the siCD95L SmartPool (siL pool). Level of knockdown relative to actin is shown.
p values were calculated using a t test. *p < 0.01; **p < 0.001; ***p < 0.0001. ns, not significant. See also Figures S1 and S2 and Tables S1 and S2.a nontargeting shRNA lentivirus (pLKO-scr), with L1 or L3, or with
the CD95 targeting shRNA R6 in the absence of puromycin (Fig-
ure S1C). This resulted in severely reduced growth followed by
cell death induction peaking at around 7 days postinfection (Fig-
ure S1C). These data suggested that cancer cell lines start dying
days after CD95L or CD95 knockdown.
To exclude a contribution of lentiviral gene products to the
observed cell death, we tested whether targeting CD95L with
siRNAswould also induce cell death in cancer cells. Transfecting
MCF-7 cells once with a low amount of CD95L-targeting siRNA
SmartPool (5 nM) caused a significant reduction of CD95L pro-
tein resulting in about 40% growth inhibition (as assessed by
MTS assay) after 3 days with little cell death detected even after
4 days of transfection (as assessed by nuclear propidium iodide
[PI] staining) (Figure 1C), suggesting different thresholds for
growth inhibition and cell death induction. To achieve a sus-
tained knockdown, we serially transfectedMCF-7 or HeyA8 cells
three times with either a CD95L-specific siRNA SmartPool or
a control pool of four nontargeting (scrambled [scr]) siRNAs.Both MCF-7 and HeyA8 cells responded to the CD95L knock-
down with substantial cell death (Figure 1D).
Awidely used control to establish the specificity of knockdown
is to test more than one siRNA/shRNA. A summary of all si/
shRNAs tested in this study and their target sites in either the
CD95L or CD95 mRNA is shown in Figure S2A. In the case of
CD95L, a total of 12 si/shRNAs targeting nonoverlapping se-
quences across the entire CD95L mRNA induced cell death in
multiple cell lines at levels up to 100%. We tested the four
siRNAs that were part of the CD95L-specific SmartPool individ-
ually in MCF-7 cells (Figure 1E). Each of the four CD95L-specific
siRNAs significantly induced cell death. The most active siRNA
was siL3. In order to further establish specificity of the CD95L
targeting, we mutated this oligonucleotide in six positions (Fig-
ure 1F). This reduced the ability to induce cell death by >80%.
Although wild-type (WT) siL3 significantly knocked down
CD95L in MCF-7-CD95L cells, the mutated version did not, sup-
porting the activity of siL3 to induce cell death (Figure 1F). These
data confirm that in order to kill cancer cells by eliminatingCell Reports 7, 208–222, April 10, 2014 ª2014 The Authors 209
Figure 2. DICE Affects Cancer Cells in a Manner Independent of Common Oncogenic Lesions
(A) Quantification of growth inhibition (MTS and SRB assay) and cell death (nuclear PI staining) of HCT116 parental and HCT116 TP53/ cells infected with
inducible shRNA constructs against CD95 (R6) or CD95L (L3) after incubation with or without Dox for 5 days. Values represent mean fold changes + SD
normalized to Dox. p values were calculated using a t test.
(B) Left panel: western blot analysis for CD95, DICER, and actin in HCT116 parental and HCT116 DICER/ cells 5 days after infection with the pLKO-R6 or pLKO-
L3 constructs. Center panel shows real-time PCR quantification of miR-34a and miR-21 in HCT116 parental and HCT116 DICER/ cells. Right panel shows
(legend continued on next page)
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CD95L, knockdown with either shRNAs or siRNAs needs to be
both efficient and sustained.
Arrayed shRNA Lethality Screens Identify CD95L and
CD95 as Genes Critical for the Survival of Cancer Cells
We collaborated with the HTS Core Facility at Memorial Sloan-
Kettering Cancer Center (MSKCC) to investigate whether CD95
and CD95L were ever nominated as survival gene candidates
in its lethality screens because it is among the very few groups
in the world performing arrayed shRNA screening against The
RNAi Consortium 1 (TRC1) library of 80,598 shRNAs targeting
16,039 human genes (Bhinder et al., 2013). Gene nomination
was very stringent and required at least three active hairpins
out of the total of five hairpins (i.e., an H score of at least 60)
(Bhinder and Djaballah, 2012). At this level of stringency,
CD95L was detected as a survival gene in multiple cancer cell
line screens (Figure S2B). Four out of 5 shRNAs targeting
different regions of the CD95L mRNA killed at least 9 of the 12
cancer cell lines tested. Knockdown of CD95 was also effective,
killing 7 of the 12 cancer cell lines. The CD95L shRNA was found
to have an average H score of 86. CD95L was identified as 1 of
651 genes (4.1% of all tested genes) to be critical for the survival
of 75% of the cancer cell lines (data not shown). Many of the
survival genes that were identified were predicted due to their
critical role in cell cycle/cell division (Table S2). The combined
data indicated that cancer cell dependency on CD95L/CD95
for survival results in substantial cell death when either CD95
or CD95L is eliminated. For simplicity, we refer to cell death
resulting from the loss of CD95 or CD95L as DICE.
DICE Is Not Affected by Common Oncogenic Lesions
To trigger DICE in amore controlled fashion, we used a Tet-indu-
cible lentiviral vector expressing GFP (pHIV7-TetR-IRES-GFP
[pTIG]) and also modified it to express a puromycin-resistance
gene instead of GFP (pTIP). Both vectors include cassettes for
expression of the CD95-specific shRNA R6 (i.e., pTIP-R6) or
the CD95L-specific shRNAs L1 or L3 (i.e., pTIP-L1 or pTIP-L3).
Addition of the tetracycline analog doxycycline (Dox) induced
efficient knockdown of CD95 or CD95L in different cell lines (Fig-
ures S3A–S3C). In most cell lines, partial knockdown of either
CD95 or CD95L was detectable 1 day after addition of Dox,
reaching a maximum after 4 days (Figures S3A–S3C; data not
shown). Similar to the cells infected with CD95 and CD95L-spe-
cific lentiviral shRNAs, Dox-induced knockdown of CD95 or
CD95L in multiple cell lines caused substantial cell death asquantification of DNA degradation in HCT116 parental and HCT116 DICER/ c
independent cultures). p values were calculated by a t test.
(C) NB7 parental and NB7-caspase-8 cells were infected with an inducible shRNA
analysis of caspase-8 (left), phase-contrast image (middle), and death assay (righ
cultures). Two independent experiments were quantified, yielding similar results.
(D) Left panel: western blot analysis for CD95 and Bcl-xL in MCF-7 Fas-vector (FV)
R6. Center panel shows quantification of DNA degradation in MCF-7(FV) and M
infection with pLKO-scr, pLKO-R6, or pLKO-L3 for 10 days (mean + SD of three i
similar results. p values were calculated by ANOVA.
(E) NOFs or immortalized NOFs were infected with either pLKO-scr, pLKO-R6 or
7 days after infection. Right panel shows cell death quantified by trypan blue staini
fold change relative to the cells infected with pLKO-scr (mean + SD of three inde
**p < 0.001; ***p < 0.0001; ns, not significant. See also Figures S3 and S4.evidenced by the appearance of rounded up, detached cells
and DNA fragmentation as well as reduced viability as measured
by MTS or sulforhodamine B (SRB) assays (Figures S3D–S3G;
data not shown) with no cell death in Dox-treated cells express-
ing a pTIP control vector (Figures S3E, S3F, 2A, and 2C) or
pTIP-scr (data not shown).
To test whether DICE can be effective in cancer cells carrying
common oncogenic lesions, we triggered DICE in cells lacking
expression of p53, DICER, or caspase-8 or overexpressing Bcl-
xL. First, we infected parental HCT116 andHCT116 TP53
/ cells
with the pTIP-R6 or the pTIP-L3 virus. Addition of Dox induced
cell death in both cell lines within 3 days, monitored in three
different ways (Figure 2A), consistent with the fact that DICE
could be triggered in 15 tested cell lines irrespective of their
p53 status (Table S1). Cancer cells often delete or downregulate
the microRNA (miRNA)-processing enzyme DICER, resulting
in globally reduced expression of miRNAs (Zhang et al., 2006).
DICE was effectively triggered by both knockdown of CD95 or
CD95L in DICER-deficient HCT116 cells (Figure 2B). Interest-
ingly, DICER deficiency did not prevent the processing of the
expressed shRNAs as evidenced by the efficient knockdown of
endogenous CD95 in DICER-deficient HCT116 cells, yet two
expressed miRNAs (miR-21 and miR-34a) were downregulated.
To test the effect of the loss of caspase-8 on DICE, we generated
NB7 cells (a neuroblastoma cell line that carries a deletion of
both CASP8 alleles; Teitz et al., 2000) inducibly expressing
shR6 or shL3. Knockdown of CD95L resulted in the same level
of dead cells in parental NB7 cells and NB7 cells reconstituted
with full-length caspase-8 (Figure 2C).
After having tested the role of three tumor suppressors in the
execution of DICE, we tested the effect of expression of Bcl-xL,
which is frequently overexpressed in cancer.We usedMCF-7(FB)
cells expressing both exogenous CD95 and Bcl-xL (Figure 2D).
Although apoptosis induction by treatment with staurosporine
(STS) was significantly inhibited by overexpressed Bcl-xL when
compared to vector-expressing cells (MCF-7(FV)) (Figure 2D), no
reduction in DICE was observed 10 days after infection. These
data suggest that DICE can be triggered in cancer cells irrespec-
tive of the presence of a number of oncogenic lesions frequently
found in human cancers, which raises the question of whether it
affects normal cells. Isolated primary human normal ovarian fibro-
blasts (NOFs) were much more resistant to DICE triggered by
knockdown of either CD95 or CD95L when compared to NOFs
immortalizedbyexpressinghumanhTERT (Figure 2E), suggesting
that DICE preferentially affects cancer cells.ells after infection with pLKO-R6 or pLKO-L3 for 8 days (mean + SD of three
construct against CD95 (R6), CD95L (L3), or control virus (pTIP). Western blot
t) were performed 6 days after Dox treatment (mean + SD of three independent
p values were calculated using a t test. Scale bar, 100 mm.
andMCF-7 Fas-Bcl-xL (FB) cells 5 days after infection with pLKO-scr or pLKO-
CF-7(FB) cells after treatment with 1 mM STS for 18 hr, or (right panel) after
ndependent cultures). Two independent experiments were quantified, yielding
pLKO-L3. Left panel shows real-time PCR analysis of CD95 mRNA in the cells
ng 7 days after infection (including 2 days of puromycin selection). Shown is the
pendent cultures). p value was calculated using a t test.
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DICE Is Independent of Caspases, RIPK1, and MLKL
To facilitate the analysis of the cell death pathway(s) that under-
lies DICE, we generated a panel of single-cell clones from
CT26L-pTIP-L3 cells by limited dilution cloning that died
completely when CD95L was knocked down (Figures S4A–
S4C; data not shown). Cells of clone 18 (CT26L-pTIP-L3/18)
died 5 days after addition of Dox (Figure S4C; Movie S1). In
contrast, the death of clone 22 cells (CT26L-pTIP-L3/22) was
delayed (Figure S4C), consistent with the delayed knockdown
of CD95L after addition of Dox in these cells (Figure S4B).
When CT26L-pTIP-L3/18 cells were studied by time-lapse
videomicroscopy after addition of Dox, clear signs of membrane
blebbing were observed just before the cells died (Movie S2),
suggesting that caspase activation contributed to DICE.
To test whether cells died of canonical caspase-dependent
apoptosis or necroptosis mediated by the RIP1 kinase activity,
a number of cell lines including CT26L-pTIP-L3/18, CAKI-1-
pTIP-R6, HCT116-pTIP-R6, and T98G-pTIG-L3 were pretreated
with either the oligo-specific caspase inhibitor zVAD-fmk (zVAD),
the RIP1 kinase inhibitor Necrostatin-1 (Nec-1), or both (Figures
3A and 3B). When CT26L-pTIP-L3/18 cells were observed in the
presence of zVAD, none of the cells showed the typical apoptotic
morphology (inset in Figure 3A; Figure S5A; Movie S3). Neither
Nec-1 alone nor Nec-1 in combination with zVAD reduced cell
death in any of the cell lines. Although treatment of cells other
than CT26L cells with zVAD slowed down DICE (triggered by
either knockdown of CD95 or CD95L), it did not rescue cells
from death (Figure 3C). The full activity of both zVAD and Nec-
1 was established using appropriate cell death systems (Figures
S5B and S5C). Using HT-29 cells recently described with
knocked down MLKL, a critical component of the necroptosis
pathway (Zhao et al., 2012), we found that DICE does not depend
on MLKL for its execution (Figure S5D). Canonical necroptosisFigure 3. DICE Represents a Form of Necrosis Independent of RIP1 th
(A andB) CT26L-pTIP-L3/18 cells (A) or CAKI-1-pTIP-R6, HCT116-pTIP-R6, or T98
20 mMzVAD, 20 mMNec-1, a combination of both inhibitors, or DMSO for 4 days (C
assay (mean + SD of three independent cultures). One (B) to three (A) independe
(C) DNA fragmentation quantified in the indicated cells after treatment with Dox for
HCT116 cells) or Nec-1 (20 mM in T98G, 10 mM inCT26L andHCT116 cells). The da
overconfluency (mean + SD of three independent cultures). Two independent exp
ANOVA.
(D) Transmission electron micrographs of CT26L-pTIP-L3/22 and T98G-pTIG-L3
(E) Representative fluorescence-activated cell sorting (FACS) plot of CT26L-pTIP
cells with JC-1. Left gate shows intact cells. Right gate shows cells with a loss o
(F) Events (percentage) in right gate of the indicated cell lines treated as in (E) fo
cultures). Two independent experiments were quantified, yielding similar results.
(G) Transmission electron micrographs of CT26L-pTIP-L3/18 cells treated or no
arrowhead points to onion-shaped structure found instead of mitochondria. Sca
(H) Quantification of ROS production by dichlorofluorescin (DCFH) fluorescence
(HCT116), or CT26L cells treated with antimycin for 24 hr (mean + SD of three in
similar results. p values were calculated by ANOVA.
(I and J) Western blot analysis for gH2AX and H2AX in CT26L-pTIP-L3/22 and T9
MCF-7 cells were infected with pLKO control virus or pLKO-R6 (J), and western
(K) Immunofluorescencemicroscopy of CT26L-pTIP-L3/22 cells treated or not with
(green) and DAPI (blue). Scale bar, 100 mm.
(L) CT26L-pTIP, CT26L-pTIP-L3/22 (3 days Dox), and T98G-pTIG-L3 (4 days Dox
photomicrographs of comet assay show DNA migration pattern in single-cell ge
(M) Quantification of tail moment of cells in (L) expressed in arbitrary units. Values r
calculated using a t test.
**p < 0.001; ***p < 0.0001; ns, not significant. See also Figures S5 and S6 and Minduced in these cells by treatment with tumor necrosis factor
a (TNF-a), a Smac mimetic, and zVAD was significantly blocked
in the absence ofMLKL. These data suggested that during DICE,
although caspases were activated and caused membrane
blebbing, cells eventually died by a mechanism independent of
apoptosis or RIP1/MLKL-dependent necroptosis.
One of the characteristics of cells dying of DICE was that they
displayed elongated odd shapes and increased in size (Figures
S5E–S5G). This cell size increase was cell autonomous because
when HepG2 cells infected with the GFP-expressing version of
the inducible lentiviral vector pTIG-L3 were mixed 1:1 with cells
infected with control virus, only the GFP-positive cells showed
an increase in cell size after addition of Dox (Figure S5H). An in-
crease in cell size caused by an influx of water is a classic sign of
necrosis (Festjens et al., 2006). To determine the effect of DICE
on subcellular structures, we subjected CT26L-pTIP-L3/22 and
T98G-pTIG-L3 cells to transmission electron microscopy anal-
ysis 4 days after addition of Dox (Figure 3D). Cells showed
partially condensed nuclei and contained large dilated vesicles,
consistent with ongoing necrosis. Thus, whereas DICE has some
features of apoptotic cell death, it is at its core a form of necrosis.
Although the experiments with cells overexpressing Bcl-xL
(Figure 2D) suggested that the proapoptotic activity of mitochon-
dria is dispensable for the execution of DICE, mitochondria may
become dysfunctional during DICE. Indeed, by using the dyes
JC-1 (Figure 3E) and DiOC6 (data not shown), DICE in CT26L-
pTIP-L3/18, T98G-pTIP-L3, and HCT116-pTIP-R6 cells was
accompanied by a drop in mitochondrial transmembrane poten-
tial (Dcm), ameasure ofMOMP. These data suggested that CD95
and CD95L are required to maintain mitochondrial integrity in
cancer cells. This was confirmed by transmission electronmicro-
scopy. Figure 3G shows CT26L-pTIP-L3/18 cells 3 days after
knockdown of CD95L. Functional mitochondria were visible inat Leads to Mitochondrial ROS Production and DNA DSBs
G-pTIG-L3 cells (B) were incubated with or without Dox after pretreatment with
T26L cells) or 5 days (other three cell lines). Cell survival was quantified byMTS
nt experiments were quantified, yielding similar results.
up to 7 days in the presence of either zVAD (20 mM inCT26L and T98G, 10 mM in
y 7 data points for CT26L cells are not shown because cells started to die due to
eriments were quantified, yielding similar results. p values were calculated by
cells 4 days after incubation with or without Dox. Scale bars, 1 mm.
-L3/18 cells after incubation with and without Dox for 3 days after staining the
f mitochondrial transmembrane potential.
r 3 days (CT26L) or 4 days (T98G, HCT116) (mean + SD of three independent
p values were calculated by ANOVA.
t with Dox for 3 days. White arrowhead points to intact mitochondrion; yellow
le bar, 500 nm.
in cells treated with or without Dox for 2 days (CT26L), 4 days (T98G), 5 days
dependent cultures). Two independent experiments were quantified, yielding
8G-pTIG-L3 cells, 2 and 4 days after Dox treatment, respectively (I). T98G and
blot analysis was performed after 5 days.
Dox for 3 days. Cells were fixedwith paraformaldehyde and stained for gH2AX
) cells were subjected to an alkaline comet assay. Representative fluorescence
l electrophoresis stained with SYBRGreen-1.
epresent the average of all cells within a given sample population. p valueswere
ovies S2 and S3.
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these cells prior to addition of Dox (white arrowhead in Figure 3G)
but were not detectable after addition of Dox. Instead, onion-
shaped membrane structures (yellow arrowhead in Figure 3G),
which were the remnants of mitochondria, were detected.
DICE Involves ROS Production and DNA Damage
Necrotic cell death is often accompanied by production of ROS
(Festjens et al., 2006). Knockdown of CD95L in CT26L clone 18
or in T98G cells or knockdown of CD95 in HCT116 cells
resulted in a significant increase in intracellular ROS (Figure 3H).
Production of high amounts of ROS can cause DNA double-
strand breaks (DSBs), leading to DNA damage, resulting in cell
death. Inducible knockdown of CD95L resulted in an increase
in phosphorylated H2AX (gH2AX), a marker for DNA DSBs (Fig-
ure 3I). Knockdown of CD95 using shRNA lentiviruses express-
ing R6 also induced gH2AX (Figure 3J). In CT26L-pTIP-L3/22
cells undergoing DICE, gH2AX was detected as foci in the
nucleus (Figure 3K). To confirm that DSBs had occurred, cells
were subjected to a comet assay. Both CT26L/22 and T98G cells
undergoing DICE showed a pronounced increase in cells with
degraded DNA (Figures 3L and 3M).
To determine whether the production of ROS during DICE was
a key element that induces DSBs and death, cells were treated
with mitochondrially targeted vitamin E (MVE). In CT26L cells,
MVE significantly reduced ROS generated during DICE (Fig-
ure S6A), resulting in a strong reduction in gH2AX formation,
which was accompanied by a substantial reduction in DNA frag-
mentation and a reduction in cell death as monitored by MTS
assay and phase-contrast microscopy. In T98G cells undergoing
DICE, addition of MVE completely blocked ROS production and
reduced gH2AX. This, however, had no effect on cell viability and
only a minimal effect on DNA degradation (Figure S6B).
The Final Phase of DICE ResemblesMitotic Catastrophe
We sought to determine the consequences of DNA damage
observed in cells that die of DICE. We performed single-cell
analyses of CT26L pTIP-L3 clones 18 and 22 using time-lapse
video microscopy. Following addition of Dox, a significant pro-
portion of cells attempted to divide but failed, resulting in cells
with multiple or fragmented nuclei (Figures 4A and 4D; Movie
S4). Another fraction of cells rounded up and then either died
immediately or died following cytokinesis (Figure 4B; Movie
S5). When stained with DAPI, numerous cells with anaphase
bridges, evidence of failed cytokinesis, were detected (Fig-
ure S7A). In T98G-pTIP-L3 and HCT116-pTIP-R6 cells, almost
all cells that died had attempted to divide as evidenced by the
appearance of a metaphase plate just before rounding up and
dying (Figures 4C and 4D; Movie S6; data not shown). When
stained with DAPI, multiple cells were detected with massively
fragmented nuclei (Figure S7B). In addition, PI staining and
flow cytometry indicated that some of the cancer cells showed
signs of aneuploidy after initiating DICE (Figure 4E). These data
suggested that for cells to die of DICE, they have to enter mitosis.
If true, then blocking entry into the cell cycle should prevent
death. To test this directly, we arrested CT26L-pTIP-L3/18 cells
in G0 by culturing them for 2 days in medium without fetal calf
serum (FCS) and then added Dox. Serum starvation did not pre-
vent CD95L knockdown (Figure 4F); however, it resulted in a214 Cell Reports 7, 208–222, April 10, 2014 ª2014 The Authorsreduction in the percentage of dead cells from 65% to 36% (Fig-
ure 4G). Serum starvation did not, however, reduce the accumu-
lation of DNA DSBs as indicated by the appearance of gH2AX
(Figure 4F). Finally, we induced CD95L knockdown in CT26L-
pTIP-L3/18 cells by addition of Dox and after 40 hr, arrested cells
in G2/M by treating them for 10 hr with the microtubule inhibitor
nocodazole. This treatment also significantly reduced DICE (Fig-
ure 4H). Two additional compounds were found to slow down
DICE, presumably due to their activity to arrest cells in the cell
cycle (Supplemental Results; Figures S7C–S7G).
DICE Engages a Complex Cell Death Program that Is
Difficult to Block
None of the tested inhibitors of apoptosis, necrosis, mitochon-
drial integrity, ROS, or their combination completely blocked
DICE in any of the cell lines. In addition, a large number of com-
pounds targeting various cancer-relevant pathways were found
to have no effect on the execution of DICE in CT26L-pTIP-L3/
18 cells. Furthermore, four commonly used chemotherapeutic
drugs also did not inhibit or promote the execution of DICE
in either HCT116-pTIP-R6 or CAKI-1-pTIP-R6 cells after addition
of Dox (data not shown; tested compounds are listed in Table S3).
In an attempt to identify compounds that would block DICE, we
performeda smallmolecule screen using the 1,120FDA-approved
compounds of the Preswick Chemical Library (http://www.
prestwickchemical.com/index.php?pa=26)butdidnot findacom-
pound that prevented DICE at 10 mM (data not shown). To identify
components of the DICE signaling pathway, we performed a
rescue screen using 77,720 lentiviral-based shRNAs targeting
16,143 unique genes. Because using the shRNA library involved
a puromycin selection step, we generated a clone of CT26L-
pTIG-L3 cells by first sorting for GFP positivity followed by limited
dilution cloning. Similar to CT26L-pTIP-L3 or CT26L-pTIP-L3/22
cells, these cells also died quantitatively after addition of Dox (Fig-
ure S8A). Not a single clone grew out after repeated infection with
the shRNA library, suggesting that knockdown of a single gene
cannot rescuecells fromDICE (data not shown). In order to identify
genes that could at least modulate DICE, we combined the
genome-wide shRNA screen with next-generation sequencing
(Figures S8B–S8D; Supplemental Results). As a result, 169 death
attenuators (prosurvivalgenes)were identifiedaswell as907death
promoters (prodeathgenes). Bothgroupsofgenesweresubjected
to a Gene Ontology analysis using the Database for Annotation,
Visualization, and Integrated Discovery (DAVID) (Figure S8E). The
83 prosurvival genes contained a cluster of genes known to be
negative regulators of cell death. Interestingly, the most highly
enriched cluster of genes among the prosurvival genes was con-
nected to glutathione metabolism, which is consistent with ROS
being involved in the execution of DICE. In contrast, the 433 pro-
death genes were enriched in genes known to be positive regula-
tors of cell death. Consistent with our observation of DNA-
damaging stress in these cells, a highly enriched gene cluster
among the prodeath genes was involved in the stress response
and DNA repair. A number of these shRNAs that target genes
that promote DICE were tested individually, but none of them
blocked DICE (data not shown). This again suggested that DICE
cannotbe inhibitedby targeting individual genesand likely involves
activation of more than one death pathway.
Figure 4. DICE Occurs When Cells Enter Mitosis
(A–C) Single frames from a time-lapse video photographic sequence of (A) CT26L-pTIP-L3/18, (B) CT26L-pTIP-L3/22, and (C) T98G-pTIG-L3 cells, after addition
of Dox (see Movies S4, S5, and S6). Arrows in (A) indicate cells with multiple nuclei, arrow in (B) labels a dividing cell, and arrow in (C) marks a cell attempting to
divide. Scale bar, 100 mm.
(D) Quantification of cell behavior after addition of Dox to the indicated cells.
(E) FACS plots showing cell-cycle profiles of MCF-7 cells 7 days after infection with pLKO or pLKO-R6 (left panel) or HCT116-pTIP-R6 treated or not with Dox for
5 days (middle and right panels).
(F) Western blot analysis of hCD95L, gH2AX, H2AX, and actin in CT26L-pTIP-L3/18 cells after serum starvation (0.1% FCS) for 2 days, followed by treatment with
Dox for the indicated times.
(G) FACS plots and representative micrographs of CT26L-pTIP-L3/18 cells cultured in serum (10% FCS) and under starvation conditions (0.1% FCS) for 2 days
and then treated with Dox for an additional 2 days. Gate shows the sub G1 fraction. Scale bar, 100 mm.
(H) Specific cell death (fold change in sub G1 peak) in CT26L-pTIP-L3/18 cells 40 hr after addition of Dox when compared to the cells with or without treatment
with 50 nM nocodazole during the last 10 hr of incubation (mean + SD of three independent cultures). p values were calculated by ANOVA. ***p < 0.0001.
See also Figure S7 and Movies S4, S5, and S6.
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Figure 5. During DICE, DNA DSBs Cause Activation of Caspase-2, Resulting in MOMP
(A and B) Cell death quantified in the indicated cells after treatment with Dox for up to 7 days in the presence of the indicated inhibitors (zVAD and Nec-1 as in
Figure 3C; MVE: 1 mM in CT26L, 0.25 mM in T98G, and 0.2 mM in HCT116 cells). The day 7 data points for CT26L cells are not shown because cells started to die
due to overconfluency (mean + SD of three independent cultures). Two independent experiments were quantified, yielding similar results. p values were
calculated by ANOVA.
(C and D) Quantification of ROS produced (C) and changes in MOMP (D) in cells after knockdown of either CD95L or CD95. Analyses were performed 2 days
(CT26L) and 4 days (HCT116) after addition of Dox (mean + SD of three independent cultures). Three (C) and two (D) independent experiments were quantified,
yielding similar results. p values were calculated by ANOVA.
(E) Quantification of MOMP in CT26L cells 40 hr after knockdown of CD95L. Cells were pretreated for 1 hr with different caspase inhibitors as indicated (mean +
SD of three independent cultures). Two independent experiments were quantified, yielding similar results. p values were calculated using a t test.
(F) Quantification of MOMP in cells 3 days (T98G) or 4 days (HCT116) after knockdown of CD95L or CD95. Cells were pretreated for 1 hr with different caspase
inhibitors as indicated (mean + SD of three independent cultures). Two independent experiments were quantified, yielding similar results.
(G) From the bottom, DNA degradation, MOMP quantification, and ROS staining of CT26L-pTIP-L3 cells transfected with either scr siRNA or a siRNA-targeting
mouse caspase-2 (100 nM) and treated with Dox for 40 hr (mean + SD of three independent cultures). The top panel shows a western blot for caspase-2 and actin
(loading control).
(H) Quantification of DNA degradation in CT26L-pTIP-L3/18 cells 40 hr after knockdown of CD95L. Cells were pretreated for 1 hr with different caspase inhibitors
as indicated (mean + SD of three independent cultures). Three independent experiments were quantified, yielding similar results.
(I) Western blot analysis of caspase-2 and actin in CT26L-pTIP-L3 cells after addition of Dox.
(J) Caspase-2 activity assay of CT26L-pTIP-L3/18 cells 48 hr after knockdown of CD95L. Cells were pretreated with caspase inhibitors where indicated.
Etoposide treatment for 24 hr was used as a positive control (mean + SD of three independent cultures). p value was calculated using a t test.
(legend continued on next page)
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Caspase-2 Contributes to the Execution of DICE
One of the inhibitors that slowed down DICE was the caspase
inhibitor zVAD (Figure 3C). Even in CT26L-pTIP-L3/18 cells,
zVAD reduced cell death early after DICE initiation at around
40 hr (data not shown). When combined with the ROS inhibitor
MVE, zVAD slowed down DICE in different cells at early stages
(Figures 5A and 5B). Interestingly, by combining more of the in-
hibitors, early attenuation of DICE in CT26L-pTIP-L3/18 cells
was enhanced stepwise (Figure 5A). This suggests that DICE
comprises multiple subpathways that contribute to the initiation
of DICE, and we sought to determine the order of these path-
ways. Treatment with zVAD alone did not significantly affect
the production of ROS in CT26L-pTIP-L3/18 cells after knock-
down of CD95L or in HCT116-pTIP-R6 cells after knockdown
of CD95 (Figure 5C), suggesting that ROS production occurred
upstream of activation of caspases in the DICE pathway.
Interestingly, MOMP was dependent on the activation of cas-
pases (Figure 5D). To determine which caspase regulated
MOMP, a set of different caspase inhibitors was tested. Of
the tested inhibitors, inhibitors of caspase-3/caspase-7 and
caspase-8 had no effect (Figure 5E). In contrast, the caspase-
2 inhibitor zVDVAD-fmk reduced MOMP in CT26L cells
almost as effectively as zVAD. This inhibitor also reduced
MOMP in T98G and HCT116 cells undergoing DICE (Figure 5F),
and this finding was validated by knocking down caspase-2 in
CT26L-pTIP-L3/18 cells (Figure 5G). Caspase-2 is known to
be activated by DNA damage (Castedo et al., 2004). Conse-
quently, inhibition of caspase-2 significantly reduced DNA
degradation in cells undergoing DICE (Figure 5H), suggesting
that caspase-2 is upstream of DNA degradation, but down-
stream of DNA damage (DNA DSBs). Activation of caspase-2
during DICE was detected by western blotting (Figure 5I) and
by a caspase-2-specific in situ activity assay (Figure 5J). To
place caspase-2 activation in the DICE signaling pathway, we
treated cells undergoing DICE with caspase inhibitors and
monitored the formation of gH2AX (Figure 5K). Consistent with
caspase-2 being downstream of DSBs, treatment of cells with
the caspase-2 inhibitor did not affect formation of gH2AX. In
contrast, zVAD prevented DSBs, suggesting that another
caspase-dependent pathway independent of ROS must be
contributing to DSBs that are seen during DICE. The data sug-
gest that a loss of either CD95 or CD95L in cancer cells causes
metabolic stress, loss of mitochondria, production of mito-
chondrial ROS, and DNA damage, followed by an inability of
cells to undergo proper cytokinesis. In summary, DICE is remi-
niscent of a necrotic form of mitotic catastrophe with signs of
apoptosis.
Evidence for Necrosis Induction after Knockout ofCD95
in a Mouse Model of Ovarian Cancer
We previously demonstrated that in a model of endometrioid
cancer, deletion of CD95 in the ovarian surface epithelium(K) Western blot analysis of gH2AX and actin in CT26L-pTIP-L3/18 cells 40 hr afte
inhibitors.
(L) Schematic illustrating the DICE subpathway in CT26L cells that results in a
protected by the expression of both CD95 and CD95L. For details, see text.
*p < 0.01; **p < 0.001; ***p < 0.0001; ns, not significant. See also Tables S3 andof LSL-KrasG12D/WTPtenloxP/loxPCD95loxP/loxP mice severely
reduced tumor formation (Chenet al., 2010).However, the reason
for the failure of tumors to develop remained unclear. Recently, a
spontaneous mouse model of ovarian cancer involving the same
genetic lesions, butwith adifferent delivery ofCre,wasdescribed
by Mullany et al. (2011). In this model, LSL-KrasG12D/WT
PtenloxP/loxPmice crossedwithmice expressing theCre recombi-
nase under the control of the anti-Muellerian hormone receptor
2 (Amhr2-Cre) develop a low-grade form of serous epithelial
ovarian cancer at 5–10 weeks of age (Mullany et al., 2011). In
contrast to the model of endometrioid cancer used in our previ-
ous study in which a rapid and acute expression of Cre was
achieved by injecting adenoviral Cre into mouse ovaries,
Amhr2-drivenCre is expressed gradually beginning at embryonic
day 3 and continuing until 7 months of age (Fong and Kakar,
2009). To determine the contribution of CD95 to this form
of ovarian cancer, we crossed CD95loxP/loxP into the LSL-
KrasG12D/WTPtenloxP/loxPAmhr2Cre/WT mice (Figure S9A). In 40-
or 80-day-oldmice not expressingAmhr2-Cre, we did not detect
a significant difference in the size of the ovaries in mice express-
ing WT CD95, CD95+/loxP, or CD95loxP/loxP (Figure 6A; data not
shown). In contrast, all the ovaries from LSL-KrasG12D/WT
PtenloxP/loxPCD95loxP/loxPAmhr2Cre/WT mice were substantially
larger than the ovaries from overall WT (normal) mice (Figures
6A, 6E, and S9C). Unexpectedly, the ovaries from LSL-
KrasG12D/WTPtenloxP/loxPCD95loxP/loxPAmhr2Cre/WT mice were
significantly larger than their CD95 WT counterparts (Figures
6A, 6E, and S9C). A histological analysis showed that in WT
mice, only the single layer of ovarian surface epithelial (OSE)
cells was positive for cytokeratin 8/18 (CK8/18) (Figure 6Bb).
In contrast, ovaries from approximately 80-day-old mutant
mice expressing CD95 contained CK8/18-positive low-grade
serous ovarian cancer cells (Figures 6Ca, 6Cb, 6Da, and 6Db).
The cancer developed predominantly on the surface of
the ovaries (see Figure S9C). In contrast, in the ovaries from
LSL-KrasG12D/WTPtenloxP/loxPCD95loxP/loxPAmhr2Cre/WT mice,
extended areas of the cancerous ovarieswere necrotic with large
numbers of infiltrating immune cells (Figures 6Cc, 6Dc, 6F, and
S9C). The large degree of hemorrhage that was found in the
majority of CD95-deficient ovaries, but not in cancerous CD95-
expressing ovaries, likely accounted for the overall size differ-
ence between cancerous ovaries expressing CD95 and lacking
CD95 expression. Areas of cancerous tissue were also found in
the CD95mutant mice, and they weremostly in foci in the interior
ofwhatwas left of theovaries (Figures 6CcandS9C). In oneCD95
mutant mouse, we detected classical necrotic tumor tissue with
the presence of ghost cells (Figures 6Cdii and 6Dd). This necrotic
tissue was not in the center of the tumor where necrosis often
occurs due to hypoxic conditions but, rather, at the periphery of
the ovary where ovarian cancer was found in most CD95 WT
cancerous mice. This finding is consistent with tumor cells
lacking CD95 expression undergoing necrosis.r knockdown of CD95L. Some cells were pretreated with the indicated caspase
ctivation of caspase-2 (blue arrows), which causes MOMP. Cancer cells are
S4.
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Figure 6. Detection of Necrosis in Cancerous Ovaries from CD95-Deficient KrasG12D/WT Pten/ Mice
(A) Representative images of ovaries from 80-day-oldKrasG12D/WTPten/mice expressing either WTCD95 (center) or lacking CD95 expression (bottom). Normal
ovaries from an age-matched LSL-KrasG12D/WTPtenloxP/loxPCD95loxP/loxP mouse (without Amhr2-Cre expression) are shown as control (top).
(B) (a) Hematoxylin and eosin (H&E)-stained normal ovary from a 83-day-old LSL-KrasG12D/WTPtenloxP/loxPCD95loxP/loxP mouse (#1046). (b) CK8/18 staining of the
boxed area of an adjacent section in (a) is shown.
(C) (a–d) Low-power images of H&E and CK8/18-stained ovaries from LSL-KrasG12D/WTPtenloxP/loxPAmhr2-Cre mouse expressing WT CD95 (a and b; #1317) or
lacking CD95 expression (c and d; #1254).
(D) (a and b) High-power images of boxed regions in (Ca) and (Cb), respectively. (c and d) High-power images of boxes i and ii in (Cd), respectively, are shown.
(E–G)Morphometric analysis of ovary size (E), area of tissue hemorrhage (F), and area of cancerous tissues as assessed throughCK8/18 staining (G). Both ovaries
of the six LSL-KrasG12D/WTPtenloxP/loxP CD95loxP/loxP mice (normal) and the four LSL-KrasG12D/WTPtenloxP/loxPCD95loxP/loxPAmhr2-Cre mice (cancer) were
analyzed. p values were calculated using a t test. ns, not significant.
See also Figure S9.
218 Cell Reports 7, 208–222, April 10, 2014 ª2014 The Authors
Lack of Cancer Formation in Mice Deficient for CD95 in
the Ovaries
Given the inefficiency of Amhr2-Cre to recombine target genes
(Fong and Kakar, 2009), we wondered whether the tumors that
were detected in the LSL-KrasG12D/WTPtenloxP/loxPCD95loxP/loxP
Amhr2Cre/WT mice had fully recombined CD95 alleles or whether
they still expressed CD95 protein. We therefore stained the
ovaries from the four mice with the LSL-KrasG12D/WT
PtenloxP/loxPCD95loxP/loxPAmhr2Cre/WT genotype, which should
lack CD95 expression, with an anti-mouse CD95 antibody and
analyzed the expression of CD95 in the CK8/18-positive tumor
regions (Figure 7A; data not shown). CD95 expression was
elevated in all tumor areas when compared to CK8/18-negative
benign tissue (Figure 7B). Examples for two of the CD95 mutant
mice are shown in Figure 7A. In both cases, strong cytosolic
staining was detected for both CK8/18 and CD95 only in the tu-
mor cells, but not in the stromal or infiltrating cells (Figures 7Ad,
7Ae, 7Ai, and 7Aj). The immunohistochemistry data suggested
that almost all cancer cells that formed in the ovaries with a
CD95-deficient genotype in fact expressed CD95. To confirm
this finding, we isolated cancer cells from the ascites of the
CD95 mutant mouse #1043 and a CD95 heterozygous mouse
by long-term culture (15 passages) and then set up single-cell
cloning at 0.5 cells per well. Only clones that were derived
from a single cell were selected for genotyping, effectively
excluding contamination by noncancer cells (Figure 7C). Three
clones derived from a LSL-KrasG12D/WTPtenloxP/loxPCD95loxP/WT
Amhr2Cre/WT mouse as well as five clones derived from a LSL-
KrasG12D/WTPtenloxP/loxPCD95loxP/loxPAmhr2Cre/WT mouse were
randomly selected for analysis. In all eight clones, both Pten
alleles were deleted (Figure 7C), and the LSL-KrasG12D gene
was recombined (data not shown). In contrast, of the five
CD95 knockout (KO) clones, four had recombined only one
CD95 locus, and one (clone 6) retained both CD95 alleles in
WT configuration (Figure 7C, lanes 4–8). Of the three
clones heterozygous for CD95, only one had recombined
CD95WT/loxP, and two clones had both a WT CD95 and an
intact CD95loxP allele (Figure 7C, lanes 1–3). Remarkably, all
eight clones had at least one intact CD95 allele as evidenced
by the presence of exon 9 (Figure 7C). Finally, we performed
western blot analysis for CD95. Although the expression of
CD95 varied greatly between the isolated clones (even among
the clones isolated from CD95 WT mice), all tested clones ex-
pressed detectable CD95, confirming the PCR analysis and
the immunohistochemistry. Interestingly, clone 7 isolated from
the CD95 KO mouse expressed CD95 protein at a level similar
to what was expressed in the heterozygous clone 2 (Fig-
ure 7D, lanes 6 and 5). These data suggest that CD95 is
critical for the survival of the cells in this type of cancer, and
the necrosis observed in ovaries with deleted CD95 was likely
caused by the elimination of CD95. It appeared that cells could
only become cancerous if Cre had selectively recombined
LSL-KrasG12D and deleted Pten without affecting the CD95 lo-
cus. In order to test whether cancer cells from these mice with
ovarian cancer are also dependent on CD95 stimulation by
CD95L for their survival, we sequentially transfected a cell line
derived from these mice that expresses CD95 (P1 in Figure 7D,
lane 8) with two siRNAs targeting mouse CD95L (Figure S9E).This induced both significant growth reduction and cell death.
These data support a crucial role for CD95 in the survival of
ovarian cancer cells.
Lack of Cancer Formation in Mice Deficient for CD95 in
the Liver
Prompted by the data on the role of CD95 in the model of low-
grade serous ovarian cancer, we revisited our previous obser-
vation that liver cancer was reduced by 50% in mice lacking
CD95 expression in the liver (CD95loxP/loxPAlb-Cre mice) in a
model of chemically induced liver cancer (Chen et al., 2010).
The expression of Cre driven by the albumin promoter has
also been reported to be quite inefficient (Postic and Magnuson,
2000). We therefore took liver sections of four randomly chosen
WT and two CD95 liver KO mice 8 months after injection with
diethylnitrosamine (DEN) and stained them for CD95. In WT
mice, numerous cancerous liver nodules were detected. We
detected upregulation of CD95 in the cancerous lesions when
compared to the surrounding benign liver tissue (Figure 7E;
data not shown). Interestingly, a clear staining of CD95 was
also found in the liver nodules that had formed in the CD95/
mice (Figure 7F). This was established by using two indepen-
dent CD95 antibodies (one mouse monoclonal and one rabbit
polyclonal). Quantification of CD95 staining in nodules detected
in sections of each liver showed that there was no significant
difference in the CD95 expression between cancer nodules
that had formed in WT mice when compared to CD95loxP/loxP
Alb-Cre mice (Figure 7G). These data suggest that similar to
the ovarian cancer models, liver tumors that lack CD95 expres-
sion barely if at all formed. When magnified, it became clear that
most of the CD95 staining in tumor nodules was found in intra-
cellular structures (Figure 7H), suggesting that the tumor-pro-
moting activity of CD95 may occur intracellularly. In summary,
our data indicate that CD95 and CD95L do not just promote
tumor growth, but they are also crucial for the survival of solid
cancer cells.
DISCUSSION
We report that knockdown of either CD95 and/or CD95L in 15
cancer cell lines, which represent 8 different types of solid can-
cers, caused substantial induction of cell death in every cell
line. In addition, analysis of the data on 12 arrayed genome-
scale shRNA screens identified CD95L as a gene critical for
the survival of cancer cells. CD95 was also identified in the
lethality screens, however, with less potency than CD95L.
Finally, we provide evidence that in two genetic mouse tumor
models of ovarian and liver cancer, cancer cells that form still
express CD95, confirming the in vivo findings that cancer cells
barely develop in the absence of CD95. DICE is characterized
by cell swelling, the appearance of large dilated vacuoles, gen-
eration of ROS, and DNA DSBs. This is followed by reduction in
cell growth, activation of caspase-2 resulting in MOMP, and
ultimately, cell death (Figure 5L). Activation of effector caspases
allows the cells to bleb and likely also contributes to DNA
degradation. However, inhibiting caspases did not prevent cells
from undergoing DICE. In addition, blocking ROS and subse-
quent DSBs also did not prevent the cells from dying. CellsCell Reports 7, 208–222, April 10, 2014 ª2014 The Authors 219
(legend on next page)
220 Cell Reports 7, 208–222, April 10, 2014 ª2014 The Authors
can die earlier but eventually die by a form of mitotic catastro-
phe at the first attempt to undergo cytokinesis. DICE is inde-
pendent of the initiator caspase-8. It is a form of necrosis but
does not depend on the RIP1/MLKL-containing necrosome
because neither Nec-1 treatment nor MLKL knockdown
attenuated it. DICE can kill cancer cells independently of p53
or DICER expression and is not affected by overexpression of
Bcl-xL.
Although DICE was initially discovered in cancer cell lines, our
data from mouse tumor models of low-grade serous ovarian
cancer and liver cancer suggest that CD95 may also be required
for the survival of cancer cells in vivo (see Supplemental Discus-
sion). Based on evidence from both CD95 and CD95L KO mice
that do not show signs of cell death or growth deficiencies in
any tissue outside the immune system (Adachi et al., 1995; Kar-
ray et al., 2004), we predicted that DICE preferentially affects
cancer cells with little effect on normal cells. This prediction
was supported by the finding that hTERT-immortalized fibro-
blasts were more susceptible to DICE triggered by either CD95
or CD95L knockdown than nonimmortalized fibroblasts (see
Figure 2E).
Although inhibition of caspases did not block DICE, it signifi-
cantly slowed it down at least at earlier time points. The caspase
most significant for DICE was caspase-2. Consistent with its role
in DICE, caspase-2 is known to be activated by DNA damage
and has functionally been linked to mitotic catastrophe (Castedo
et al., 2004). Caspase-2 is an attractive candidate for being a
component of the DICE pathway because it plays a role in cell-
cycle maintenance (Dorstyn et al., 2012) and acts as a tumor
suppressor in mouse models of lymphoma and breast cancer
(Ho et al., 2009; Parsons et al., 2013).
In summary, DICE comprises multiple death pathways, and
we did not find a single small molecule inhibitor or shRNA
that can block DICE. The only compounds that could at least
temporarily halt the execution of DICE were compounds that
cause cell-cycle arrest, which is consistent with our finding
that cells without CD95 or CD95L expression cannot traverse
through cytokinesis. DICE may therefore be an interesting
new way to kill cancer cells without them easily acquiring
resistance.Figure 7. Cancerous Cells Developing from LSL-KrasG12D/WTPtenloxP
Mice Express CD95
(A) Immunohistochemistry analysis of sections of ovaries from two LSL-KrasG12D
ovaries. (c)–(e) are the higher magnifications of H&E, CK8/18, and CD95 staining o
and CD95 staining of areas boxed in (f) and (g). T, tumor; H, hemorrhage; S, stro
(B) Quantification of CD95 staining intensity in ovaries of four KrasG12D/WTPten
(bottom). Ovary #2 in mouse #1476 had so much infiltration that neither benign no
benign tissue.
(C) PCR analysis of cloned cell lines derived frommice with ovarian cancer hetero
right loxP site in the CD95 gene.
(D) Western blot analysis of single-cell clones derived from mice with a genotype
extracts of a cell line (P1) derived from KrasG12D/WTPten/mice (Mullany et al., 20
nontargeting shRNA (scr) as well as liver extracts from WT and CD95loxP/loxPAlb-
(E) H&E and CD95 staining of a liver section of a WT mouse 8 months after injec
(F) H&E and CD95 staining of a liver section of a CD95loxP/loxPAlb-Cremouse 8 mo
[mu] or a rabbit polyclonal [rb] CD95 antibody).
(G) Quantification of CD95 expression in all nodules in sections from twoCD95loxP/
from CD95 KO livers, and 20 nodules were analyzed from WT livers. Liver nodule
(H) Magnification of the CD95-stained tumor region in (F) boxed in red.EXPERIMENTAL PROCEDURES
Generation of the TetOn shRNA-Expressing Cells
The pTIG lentiviral vector was a kind gift from Dr. John J. Rossi (Beckman
Research Institute of the City of Hope, Duarte) (Aagaard et al., 2007). To
replace the GFP sequence with a puromycin-resistance sequence, the puro-
mycin-resistance gene was excised from pUC57-puro using PmlI/BsrgI and
inserted into pTIG-U6tetOshRNA. The shRNA oligonucleotides (shScr, L1,
L3, and R6) were obtained from IntegratedDNA Technologies andwere cloned
directly into the BsaBI/SphI restriction sites in pTIG or pTIP. To generate cells
stably expressing the inducible shRNA constructs, cells were either infected
with pTIG vectors and sorted for GFP expression using a Beckman Coulter
MoFlo high-speedmultilaser droplet cell sorter or were infected with pTIP vec-
tors and maintained in puromycin-containing medium unless Dox was added.
shRNAs were induced by adding 0.1 mg/ml Dox unless otherwise indicated.
Generation of KrasG12D/WTPtenloxP/loxPCD95loxP/loxPAmhr2-Cre Mice
All experimental protocols followed NIH guidelines and were approved by the
institutional animal care and use committees of Northwestern University. To
obtain female littermates with CD95loxP/loxP present or absent within the spon-
taneous ovarian cancer mouse model, founder mice on a genetic background
previously published (Mullany et al., 2011) were bred in two steps (see Fig-
ure S9A). In the parental generations, the Amhr2-Cre+ gene was bred only
through the male lineage, whereas the LSL-KrasG12D gene was only bred
through the female lineage. The genotype of the original parents for the sire
was KrasWT/WT PtenloxP/loxP CD95WT/WT Amhr2-Cre and for the dam was
LSL-KrasG12D/WT PtenloxP/loxP CD95loxP/WT. In the F1 generation, the genotype
of the sire was KrasWT/WT PtenloxP/loxP CD95WT/loxP Amhr2-Cre/WT, and the
genotype of the dam was LSL-KrasG12D/WTKrasWTPtenloxP/loxP CD95WT/loxP.
In the F2 generation, both parents had the genotype CD95loxP/WT to allow for
both CD95WT/WT (‘‘CD95-WT mice’’) and CD95loxP/loxP (‘‘CD95-KO mice’’) in
the next generation. The expected ratio for each female genotype was 1:32.
Additional Experimental Procedures can be found in the Supplemental
Experimental Procedures.
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of WT, heterozygous, or homozygous deletion of CD95. As a positive control,
11) are shown infected with a lentiviral shRNA-targetingmouse CD95 (R28) or a
Cre (KO) mice. The asterisk (*) indicates an unspecific band.
tion of DEN.
nths after injection of DEN using two different antibodies (a mouse monoclonal
loxPAlb-Cre and 4CD95loxP/loxPmice. A total of 15 tumor noduleswere analyzed
s found in individual mice are shown in different colors. ns, not significant.
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